778 related articles for article (PubMed ID: 23864173)
21. Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence.
Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
Clin Ther; 2016 Mar; 38(3):478-93.e1-16. PubMed ID: 26922297
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness analysis of apixaban compared to low-molecularweight heparins and vitamin k antagonists for treatment and secondary prevention of venous thromboembolism.
Elías I; Oyagüez I; Alvarez-Sala LA; García-Bragado F; Navarro A; González P; De Andrés-Nogales F; Soto J
Farm Hosp; 2016 May; 40(3):187-208. PubMed ID: 27145388
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of prophylactic low molecular weight heparin in pregnant women with a prior history of venous thromboembolism.
Johnston JA; Brill-Edwards P; Ginsberg JS; Pauker SG; Eckman MH
Am J Med; 2005 May; 118(5):503-14. PubMed ID: 15866253
[TBL] [Abstract][Full Text] [Related]
24. No Increased Risk of Venous Thromboembolism in High-Risk Patients Continuing Their Dose of 75 mg Aspirin Compared to Healthier Patients Given Low-Molecular-Weight Heparin.
Hovik O; Amlie EJ; Jenssen KK
J Arthroplasty; 2021 Oct; 36(10):3589-3592. PubMed ID: 34176693
[TBL] [Abstract][Full Text] [Related]
25. Comparative effectiveness of direct oral anticoagulants versus low-molecular weight heparins for the prevention of venous thromboembolism after total hip or knee replacement: A nationwide database cohort study.
Blin P; Samama CM; Sautet A; Benichou J; Lignot-Maleyran S; Lamarque S; Lorrain S; Lassalle R; Droz-Perroteau C; Mismetti P; Moore N
Pharmacol Res; 2019 Mar; 141():201-207. PubMed ID: 30583081
[TBL] [Abstract][Full Text] [Related]
26. Extended dalteparin prophylaxis for venous thromboembolic events: cost-utility analysis in patients undergoing major orthopedic surgery.
Dranitsaris G; Stumpo C; Smith R; Bartle W
Am J Cardiovasc Drugs; 2009; 9(1):45-58. PubMed ID: 19178131
[TBL] [Abstract][Full Text] [Related]
27. Extended-duration low-molecular-weight heparin prophylaxis following total joint arthroplasty.
Whang PG; Lieberman JR
Am J Orthop (Belle Mead NJ); 2002 Sep; 31(9 Suppl):31-6. PubMed ID: 12349893
[TBL] [Abstract][Full Text] [Related]
28. [Cost-effectiveness analysis of apixaban compared to dabigatran in the prevention of venous thromboembolism in patients subjected to total knee or hip replacement].
Gómez-Cerezo JF; Gómez-Arrayás I; Suárez-Fernández C; Betegón-Nicolás L; de Salas-Cansado M; Rubio-Terrés C
Rev Esp Cir Ortop Traumatol; 2012; 56(6):459-70. PubMed ID: 23594943
[TBL] [Abstract][Full Text] [Related]
29. Pharmacological thromboprophylaxis and its impact on venous thromboembolism following total knee and hip arthroplasty in Korea: A nationwide population-based study.
Yhim HY; Lee J; Lee JY; Lee JO; Bang SM
PLoS One; 2017; 12(5):e0178214. PubMed ID: 28542415
[TBL] [Abstract][Full Text] [Related]
30. Comparative Effectiveness and Safety of Drug Prophylaxis for Prevention of Venous Thromboembolism After Total Knee Arthroplasty.
Cafri G; Paxton EW; Chen Y; Cheetham CT; Gould MK; Sluggett J; Bini SA; Khatod M
J Arthroplasty; 2017 Nov; 32(11):3524-3528.e1. PubMed ID: 28634095
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness Analysis for Apixaban in the Acute Treatment and Prevention of Venous Thromboembolism in the Netherlands.
de Jong LA; Dvortsin E; Janssen KJ; Postma MJ
Clin Ther; 2017 Feb; 39(2):288-302.e4. PubMed ID: 28139289
[TBL] [Abstract][Full Text] [Related]
32. Cost effectiveness of dalteparin for preventing venous thromboembolism in abdominal surgery.
Heerey A; Suri S
Pharmacoeconomics; 2005; 23(9):927-44. PubMed ID: 16153135
[TBL] [Abstract][Full Text] [Related]
33. Low molecular weight heparin for the prevention and treatment of venous thromboembolism.
Raskob GE
Curr Opin Pulm Med; 1996 Jul; 2(4):305-10. PubMed ID: 9363157
[TBL] [Abstract][Full Text] [Related]
34. A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention.
Revankar N; Patterson J; Kadambi A; Raymond V; El-Hadi W
Postgrad Med; 2013 Jul; 125(4):141-53. PubMed ID: 23933902
[TBL] [Abstract][Full Text] [Related]
35. Safety and effectiveness of aspirin and enoxaparin for venous thromboembolism prophylaxis after total hip and knee arthroplasty: a systematic review.
Nadi S; Vreugdenburg TD; Atukorale Y; Ma N; Maddern G; Rovers M
ANZ J Surg; 2019 Oct; 89(10):1204-1210. PubMed ID: 30989803
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain.
Monreal M; Folkerts K; Diamantopoulos A; Imberti D; Brosa M
Thromb Haemost; 2013 Nov; 110(5):987-94. PubMed ID: 23965805
[TBL] [Abstract][Full Text] [Related]
37. [Case-control study on three antithrombotic agents for the prevention of venous thromboembolism after unilateral total knee arthroplasty].
Miao SG; Zhang XG; Lu JH; Yang Y; Lu N
Zhongguo Gu Shang; 2015 Oct; 28(10):893-6. PubMed ID: 26727779
[TBL] [Abstract][Full Text] [Related]
38. Perioperative antithrombotic management in joint replacement surgeries.
Lee HL; Chiu KY; Yiu KH; Ng FY; Yan CH; Chan PK
Hong Kong Med J; 2013 Dec; 19(6):531-8. PubMed ID: 24141860
[TBL] [Abstract][Full Text] [Related]
39. Economic evaluation of the prophylaxis for thromboembolism in critical care trial (E-PROTECT): study protocol for a randomized controlled trial.
Fowler RA; Mittmann N; Geerts WH; Heels-Ansdell D; Gould MK; Guyatt G; Krahn M; Finfer S; Pinto R; Chan B; Ormanidhi O; Arabi Y; Qushmaq I; Rocha MG; Dodek P; McIntyre L; Hall R; Ferguson ND; Mehta S; Marshall JC; Doig CJ; Muscedere J; Jacka MJ; Klinger JR; Vlahakis N; Orford N; Seppelt I; Skrobik YK; Sud S; Cade JF; Cooper J; Cook D; ;
Trials; 2014 Dec; 15():502. PubMed ID: 25528663
[TBL] [Abstract][Full Text] [Related]
40. Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost-effectiveness analysis.
Marchetti M; Pistorio A; Barone M; Serafini S; Barosi G
Am J Med; 2001 Aug; 111(2):130-9. PubMed ID: 11498067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
